Biotechnology

ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

May 27, 2026 4:30 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced plans to enter the focused ultrasound market, and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using the ClearPoint prototype system. This device was built in partnership with the SONOCARELAB, at Sungkyunkwan...

Read more

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

May 27, 2026 9:06 AM

OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million. The acquisition follows OSRH's previously announced definitive global exclusive...

Read more

FluoGuide A/S Publishes Interim Report for Q1 2026

May 27, 2026 1:30 AM

Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available as attached document to this press release and on FluoGuide's website. "The first quarter marked an important step forward for FluoGuide as we advanced FG001 toward registration-directed development in the U.S. The FDA IND authorization and Fast Track Designation provide important regulatory...

Read more

Aspira Women's Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women's Health

May 26, 2026 9:02 AM

Aspira Women's Health Inc. (OTCQX:AWHL) ("Aspira" or the "Company"), a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women's health, and Cleveland Clinic have signed an agreement to improve women's health diagnostics. Under the terms of this Master Collaboration and License Agreement, Aspira and Cleveland Clinic will collaborate on research projects focused on the discovery and validation of novel...

Read more

From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story

May 26, 2026 9:00 AM

Biotech investors spend enormous amounts of time searching for "the next big thing." Most never stop to ask a more important question: What does sophisticated pharmaceutical money actually look for before billions of dollars start moving? That distinction matters. Because the biotechnology graveyard is filled with companies that had interesting science but never figured out how to position themselves strategically inside the larger oncology...

Read more

Biovica Receives Expanded Work Order from Clinical-Stage Oncology Company for Next-Generation CDK Inhibitor Program

May 26, 2026 3:05 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, today announced an expansion of an existing Pharma Services work order from a clinical-stage biopharmaceutical company developing a next-generation CDK inhibitor for solid tumors. The expanded work order amounts to approximately USD 75,000 (SEK 700,000). The company has previously engaged Biovica in multiple projects related to its...

Read more

Vicore Pharma to Present at the Jefferies Global Healthcare Conference

May 26, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced participation in the Jefferies Global Healthcare Conference: Location: New York, New York Format: Fireside chat and 1×1 meetings Webcast: Link Presentation Date and Time: Thursday June 4th at 2:35 PM Participants: Ahmed Mousa, CEO, and Bernt van den Blink, CMO For more information,...

Read more

MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing

May 26, 2026 1:50 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced it has entered into a definitive agreement for a CHF 8.0 million equity financing with Neuro.io Group SA (Neuro.io), through which Neuro.io will acquire a strategic equity position in the Company. The proceeds will support the Company's commercial priorities, including scaling its U.S....

Read more

Cloud-Clone Laboratory Animal Center Behavioral Testing Platform Provides One-stop Solutions for Global Clients

May 25, 2026 8:00 AM

Whether a mouse behaves with curious exploration or fearful withdrawal in an unfamiliar environment, and whether it finds its way out of a complex maze relying on memory or walks randomly-these seemingly simple behavioral choices precisely reflect the cognitive function, emotional state and motor ability of laboratory animals. They also serve as a key entry point for analyzing life phenomena and advancing neuroscience research and new drug...

Read more

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

May 22, 2026 7:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce that Neuland Laboratories Limited ("Neuland") has ordered the required raw materials and is preparing to initiate Phase 1 of its macromolecule-enabled transdermal delivery development activities under the previously announced services agreement (see Company press release dated January 8, 2026) between the parties. Phase 1 of...

Read more

Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC

May 22, 2026 9:05 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced that it has filed a Registration Statement on Form 20-F (Registration Statement) with the US Securities and Exchange Commission (SEC) in connection with registration of Vicore Pharma as a reporting company under the Securities Exchange Act of...

Read more

Alligator Bioscience Comments on Henlius Update on Long-Term Follow-Up Data for HLX22

May 22, 2026 3:05 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up observations from clinical studies of HLX22. According to Henlius' communication, long-term follow-up over more than 39 months indicates that patients treated with HLX22 continue to demonstrate extended progression-free survival (PFS) at the current observation point. The update reflects ongoing...

Read more

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO

May 21, 2026 5:30 PM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of heavily pretreated patients with advanced...

Read more

Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy

May 20, 2026 9:33 AM

Flow Pharma, Inc. announced today that it's U.S. Patent application has been allowed for issuance covering a broad-spectrum treatment for Ebola virus infections, utilizing the company's proprietary microsphere delivery technology. Unlike currently available therapies that are generally designed for specific Ebola strains, their patented approach is based on the monoclonal antibody siltuximab, which binds to a toxin released after infection with...

Read more

Prolocor Announces Results of NIH-funded Study Demonstrating That Platelet FcγRIIa Identifies Cancer Patients at Increased Risk of Death and Thrombotic Events

May 20, 2026 9:00 AM

Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG™ test to identify patients at risk of thrombotic events, announced the publication of a recently completed study entitled Platelet FcγRIIa: A Novel Biomarker of Risk for Thromboembolism and Death in Cancer, in the Journal of Thrombosis and Thrombolysis. The study supported by a grant from the NIH and completed by researchers at the University of Vermont...

Read more

BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026

May 20, 2026 5:50 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, May 27, 2026 at 8:00 AM EDT / 2:00 PM CEST featuring Dmitriy Zamarin MD, PhD (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai), who will join company management to discuss the unmet need and current treatment...

Read more

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

May 19, 2026 5:30 PM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's disease ("AD"), today announced the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission ("SEC") for the quarter ended March 31, 2026. "During the first quarter, we continued to execute against our core priorities by...

Read more

Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026

May 19, 2026 8:20 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(NASDAQ Stockholm:EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, taking place May 17 to 20, 2026, in Philadelphia, PA, USA. ISPOR is a leading global conference for health economics and outcomes research, offering an important forum for scientific exchange among researchers,...

Read more

GeneTex Opens European Headquarters in Germany

May 19, 2026 4:00 AM

GeneTex, a multinational recombinant antibody and reagent manufacturer, announces the opening of its European headquarters GeneTex Europe GmbH, situated near Munich in Freising, Germany. With the establishment of this office, GeneTex has expanded its physical footprint to include Europe, North America, and Asia. GeneTex's newest location is fully operational and receiving orders from researchers in academic, industrial, and pharmaceutical...

Read more

The 2026 VinFuture Prize Receives More Than 1,800 Nominations as Its Global Nomination Network Expands Fourteenfold After Six Years

May 18, 2026 10:57 AM

After six seasons, the VinFuture Prize has not only expanded its influence in the international scientific community, but has also affirmed its position as a prestigious global prize dedicated to identifying and honoring breakthroughs with profound significance for the future of humanity. H.E. Tran Thanh Man, Chairman of the National Assembly of Vietnam, presents the 2025 VinFuture Grand Prize to the scientists whose pioneering contributions led...

Read more